Photocure fundamentale forhold (PHO)

[myk]

Jeg synes dette er helt fantastisk. Et firma som utvikler en teknologi som forbedrer bruken til blue light produktet til Photocure og potensielt øke markedet raskere og totalt. PHO er jo bare interessert i å selge Cysview så det er som hånd i hanske.

[kreinh]

Dette er gammelt nytt. Debattert i det vide og det brede tidligere…

[Hkirk]

Enig. Og dette er kursutviklingen de siste 12 mnd.

[Savepig]

Hadde de hatt emisjon nylig?

[ListeBot]

En fersk aksjonærliste for PHO er tilgjengelig for Insider-medlemmer. Ikke Insider? Les mer og prøv gratis

[Savepig]

Kan røpe at dagens topp 20 kommer til å ha MYE utlendinger som kjøper.

Fasit fra forrige uke:

Photocure småprat 2020 (PHO)

Topp 20 liste hentet ut idag gjeldende til og med tirsdag skulle det vel bli.

Såvidt jeg kan se er Morgan Stanley ny på listen.

Legger den her og @Rodjer

[InVivo]

Hva er bakgrunnen for deres plutselige inntog? Den bleike kronen?

[Savepig]

Kan godt hende det er flere i utlandet som har hatt aksjen på watch list, og så har de benyttet trifectaen som en god anledning til å starte kjøp:

1. Alle aksjer falt mye pga finanskrisen
2. Kronen svekket seg helt vanvittig en periode der, slik at de fikk 30% rabatt på norske aksjer på det meste. (Da er jo risikoen at de selger når NOK styrker seg.)
3. Photocure falt alt for mye fordi største eier ble nødt til å dumpe alle aksjer på en uke.

[InVivo]

Alle aksjer falt mye pga finanskrisen

Det som var litt spesielt var at Pho falt like mye som de prekommersielle bioteks på OB.

Forteller meg at OB ikke klarer å skille klinten fra hveten, men behandler alt av biotek med en generell tilnærming.

[TekBot]

Photocure ASA: Market update #2

Oslo, Norway, 7 April 2020: The Board of Directors and Management of Photocure
ASA (OSE:PHO) follow the COVID-19 situation closely and have implemented strict
measures to ensure the safety of patients, customers, employees and business
…

Vis børsmeldingen

partners while maintaining an uninterrupted level of service and supply. The
company today provides the second COVID-19 Oslo Stock Exchange notification to
ensure updated and transparent stakeholder information.

“The pandemic continues to bring tremendous hardship on those affected by the
virus; families, communities and business. The Photocure team expresses its
sincere gratitude to the many healthcare professionals around the world
providing lifesaving care and support. Our main priority is to ensure safe
operations and an uninterrupted supply of Hexvix[®]/Cysview[®] while maintaining
business in this new uncharted business and healthcare environment. Bladder
cancer treatments are a prioritized procedure for the healthcare systems, but we
must expect short-term postponements as resources are reallocated to prepare for
the exponentially growing number of COVID-19 patients in the coming weeks and
months,” says Daniel Schneider, President & Chief Executive Officer of
Photocure.

Photocure has adapted a framework for disclosure of COVID-19 related
information*, suggesting several topics for a risk and effect assessment,
including the following:

· COVID-19 impact on financial condition and results of operations.
Photocure comment: Bladder cancer treatments are prioritized procedures for the
healthcare systems, but Photocure expects restricted access to hospitals. Short
-term postponements of procedures and cystoscope installations will be
temporarily slowed. Hospitals are reallocating health care providers and
resources to handle the increase of COVID-19 patients. The long-term outlook
remains strong, but the visibility, especially in the U.S. remains limited for
the coming weeks and months.

· COVID-19 impact on capital and financial resources, including overall
liquidity position and outlook.
Photocure comment: The company had a cash position of NOK 123 million at the end
of March 2020 and carries no interest-bearing debt. Cost saving exercises are
being implemented to reduce cash burn through the restricted access period. In
addition, the company is pursuing various governmental subsidies and programs to
further help bridge this short-term period. Postponements of procedures will
affect the short-term kit shipments, impacting the working capital, but
Photocure has a solid financial position.

· COVID-19 impact on balance sheet and the ability to timely account for those
assets.
Photocure comment: The company expects the COVID-19 situation to have short-term
impact on the balance sheet, but an extended and profound virus situation in the
U.S. with a major and lasting impact on the business environment, may challenge
booked values.

· COVID-19 impact on impairments, increases in allowances for credit losses,
restructuring charges, other expenses, or changes in accounting judgments that
have had or are reasonably likely to have a material impact on the financial
statements.
Photocure comment: The company expects the COVID-19 situation to have impact on
the short-term financial statements, but an extended and profound virus
situation in the U.S., with a major and lasting impact on the business
environment, may affect the financial statements.

· COVID-19 impact on circumstances such as remote work arrangements adversely
affecting the ability to maintain operations, including financial reporting
systems, internal control over financial reporting and disclosure controls and
procedures.
Photocure comment: The company has implemented remote work arrangements across
its locations and is fully operational. All functions are designed to
accommodate remote work and no disruptions are expected. The main priority of
the organization is the health and welfare of all Photocure employees and
stakeholders. Business and travel policies which supported work from home and
social distancing were implemented prior to governmental orders. Where access to
hospitals and clinics is restricted because of the situation, Photocure’s sales
force maintains contact as needed through remote channels in order to guarantee
optimal service and support.

· COVID-19 impact on implementing business continuity plans.
Photocure comment: In light of the seriousness of the current COVID-19 global
health care crisis, the evolving circumstances require a different way of
working between Photocure and the health care providers. In a changing
environment, the company will continue to adapt to any new way of working to
provide our partners with uninterrupted service in treating patients with
bladder cancer. The company intends to keep the lines of communications open and
plans to offer a variety of means to keep Blue Light Cystoscopy with Cysview in
the forefront of patient care.

· COVID-19 impact on the demand for products or services.
Photocure comment: Bladder cancer treatments are prioritized procedures for the
healthcare systems, but the company expects short-term postponements, especially
in the low and medium risk patient category, as resources are reallocated to
prepare for the exponentially growing number of COVID-19 patients. In addition,
the opening of new accounts and placement of new scopes will be affected in the
short-term. The long-term outlook remains strong, but the visibility, especially
in the U.S. will stay low for the coming weeks and months.

· COVID-19 impact on supply chain.
Photocure comment: The company has increased the inventory of
Hexvix[®]/Cysview[®] to accommodate the estimated procedures through the first
quarter of 2021 and production remains at full capacity and on schedule. The
international distribution lines are uninterrupted and the inventory levels of
kits at partners and hospitals remain satisfactory.

· COVID-19 impact on human capital resources and productivity.
Photocure comment: The company has a highly specialized workforce committed to
improving patients’ lives. The majority of their work requires interaction with
healthcare providers. In the short-term, many institutions are restricting
access to protect patients, providers and suppliers from contracting COVID-19.
Photocure supports any employees willing to volunteer their medical expertise to
the communities in which they reside.
The U.S. sales team is supporting customers remotely and dedicating
administrative time to develop business plans to accelerate recovery after the
quarantine measures are lifted. Training sessions and virtual educational events
with leading urologists are also being organized and executed.

· COVID-19 impact on ability to operate and achieve business goals following
travel restrictions and border closures.
Photocure comment: Border closures do not affect the company´s national and
regional sales force. However, in many cases, hospital restrictions prohibit
supplier sales representatives from entry into the buildings. The long-term
outlook remains strong, but short-term business development initiatives will be
limited in the coming weeks following the travel restrictions and social
distancing measures.

“Photocure has a cash position of NOK 123 million at the end of March 2020 and
carries no interest-bearing debt. We have a strong underlying sales momentum in
the U.S when returning to a normalized business environment, providing a solid
platform for long-term growth. Short term business development and operations
will be affected by this unprecedented crisis in various ways, but we remain
confident in the significant commercial opportunities in the U.S. and reiterate
our long-term ambitions”, Schneider concludes.

*Division of Corporation Finance Securities and Exchange Commission CF
Disclosure Guidance: Topic No. 9. Date: March 25, 2020.

---

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA

This press release may contain product details and information which are not
valid, or a product is not accessible, in your country. Please be aware that
Photocure does not take any responsibility for accessing such information which
may not comply with any legal process, regulation, registration or usage in the
country of your origin.

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Tel: + 1-609 759-6515
Email: ds@photocure.com

Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000
Email: ed@photocure.no

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

Kilde

[kreinh]

Market Update som ventet. Trodde ikke de hadde så mye som 123 millioner i slutten av Mars. Salget av Cysview har gått bra i Q1.

[Teddy1]

Det er jo mindre enn 125 på årrslutt?

[Savepig]

Her er rammeverket PHO bruker for å rapportere:

https://www.sec.gov/corpfin/coronavirus-covid-19

[TekBot]

Photocure ASA - Annual accounts 2019

Oslo, 8 April 2020: Photocure ASA (OSE: PHO), has published the annual accounts
and annual report for the financial year 2019.

…

Vis børsmeldingen

The Company’s annual accounts for the financial year 2019, including the
financial statements and annual report for the financial year 2019, are together
with the auditor’s report attached to this notice.The documents are also
available at the Company’s website, www.photocure.com.
Photocure Annual Report
2019 (https://mb.cision.com/Public/17498/3084039/bd56fae530b02165.pdf)
For further information, please contact:
Photocure

CFO Erik Dahl
Tel: +47 450 55 000, Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, which makes
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TyrionIV]

In line with our ambition for U.S., Cysview® is well on its way to becoming the standard of care for bladder cancer patients. Keys to success are in place:

• Approval – Broader U.S. Indication into the 3x larger surveillance market
• Acceptance – AUA, EAU, SUO and many regional and local guidelines as well as the newly published Expert Consensus Guidelines for surveillance with flexible cystoscopes
• Access – Permanent and favorable reimbursement as of January 2019 and additional new codes to come in 2020.
• Activated Awareness – Demand via advocacy groups, clinics’ advertising and media
• Acceleration – Commercial investment in the U.S. to optimize the opportunity in our largest and untapped market

Photocure will maximize the return on our commercial investment by executing our plans in the largely untapped U.S. market where we expect to see our greatest returns in the form of significant and sustainable revenue and profitability growth.

[Gheno]

Asieris will assume responsibility for the manufacturing of
the Cevira product while Photocure retains responsibility for the
manufacturing of the active pharmaceutical ingredient (API).

[myk]

ja flott rapport

[solskimm]

Dette betyr vel at Photocure ikke trenger å forholde seg til Ipsen for andre markeder?

Etter hva jeg forstår har ikke Ipsen “monopol” i landene sine lengre.
Kom gjerne med innspill om dere leser det på en annen måte…

[TekBot]

Photocure - Employee incentive program

With reference to the senior management share option program in Photocure ASA
(“Photocure” or “Company”), on 7 April 2020 the Board of Directors in Photocure
resolved the issue of in total 500,000 share options for 2019.
…

Vis børsmeldingen

Primary insiders in the Company have been issued the following share options:

· Daniel Schneider, President and Chief Executive Officer, 200,000 share
options. Following the issue, Daniel Schneider holds 200,000 share options and
33,353 shares in the Company.
· Erik Dahl, Chief Financial Officer, 40,000 share options. Following the
issue, Erik Dahl holds 65,500 share options and 10,633 shares in the Company.
· Geoffrey Coy, Vice President and General Manager of US Operations, 90,000
share options. Following the issue, Geoffrey Coy holds 90,000 share options and
no shares in the Company.
· Grete Hogstad, Vice President Strategic Marketing, 25,000 share options.
Following the issue, Grete Hogstad holds 46,000 share options and 19,444 shares
in the Company.
· Kari Myren, Head of Global Medical Affairs and Clinical Development, 25,000
share options. Following the issue, Kari Myren holds 25,000 share options and
962 shares in the Company.
· Gry Stensrud, Vice President Technical Development & Operations, 25,000
share options. Following the issue, Gry Stensrud holds 51,300 share options and
7,189 shares in the Company.

All options are issued in accordance with the board of directors’ declaration on
salaries and other remuneration to the senior executive management, as approved
by Photocure’s annual general meeting held 9 May 2019 and the general terms for
the 2019 option program. The share option program and properties of the options
are described in note 24 in Photocure’s annual financial statements for 2018.
The share options have a strike price of NOK 50.72 with the exception of options
issued to Geffrey Coy with a strike price of NOK 56.83. The option issue is
determined based on achievement of Company and individual goals during 2019 with
a strike price and vesting period fixed as of the general meeting’s approval on
9 May 2019. Geoffrey Coy is issued options pursuant to his employment agreement
and with a strike and vesting period fixed as of his employment on 20 August
2019.

This information is subject of the disclosure requirements pursuant to section 5
-12 and 4-2 of the Norwegian Securities Trading Act.

Kilde

[myk]

Guidingen for 2023 står fast
Outlook
Photocure delivers transformative solutions which improve
the lives of bladder cancer patients. Based on experience and
the performance of the breakthrough bladder cancer product
Hexvix®/ Cysview®, Photocure has embarked on a stepwise
approach for continued growth. Photocure sees significant longterm potential in the global bladder cancer market and has a
defined growth strategy:
• Accelerating – Drive the breadth and depth of Hexvix®/
Cysview® usage in key accounts
• Expanding – Generate sales in new geographies and product
enhancements
• Acquiring – Synergistic or complementary products
• Transforming – Partner and in-license assets to strengthen
the bladder cancer portfolio
The U.S. continues to represent the primary growth market for
Photocure with a large untapped market opportunity exceeding
1 million procedures per year.
Based on the outlook and strategic opportunities, Photocure
targets U.S. revenues in the range of USD 70 million in 2023,
and sees significant continued revenue growth and profit
opportunities in the U.S. market beyond 2023.